Genital prevalence of HPV types and co-infection in men

Marcos P. Freire, Daniel Pires, Raphael Forjaz, Sérgio Sato, Ismael Cotrim, Mônica Stiepcich, Bruno Scarpellini, José C. Truzzi

Division of Urology, Fleury Group (MPF, IC, MS, BS, JCT); Anhembi Morumbi Medical School (MPF, DP, RF, SS,) and Federal University of São Paulo (MPF, IC, JCT) Sao Paulo, Brazil

ABSTRACT

Introduction: HPV infection is a highly prevalent sexually transmitted disease and there is evidence of the relationship of HPV infection and the development of genital warts, penile intraepitelial neoplasia, invasive penile carcinoma and cervical cancer. However, there is sparse data regarding the prevalence of HPV types and co-infection of different HPV types among men.

Objectives: To assess the prevalence of HPV subtypes infections and rates of co-infection among men.

Materials and Methods: 366 men were evaluated from March to October 2010. Men were referred to our institution for HPV diagnostic evaluation based on the following criteria: 1. presence of a genital wart; 2. presence of an atypical genital lesion; 3. absence of symptoms and a partner with a HPV diagnosis; 4. absence of symptoms and a desire to undergo a full STD diagnostic evaluation. Genital samples were collected from the urethra, penile shaft, scrotum and anus with Digene® collection and preservation kit and submitted to HPV genotype microarray detection (Papillocheck®). All men were tested for the low-risk HPV types 6-11-40-42-43-44 and for the high-risk HPV types 16-18-31-33-35-39-45-51-52-53-56-58-59-66-68-70-73-82.

Results: Of the 366 men, 11 were tested inconclusive and were excluded from the analysis. 256 men (72.1% of the men from the cohort referred to our institution) tested positive with genotype micro-array detection and 99 tested negative. The most prevalent HPV-subtypes in the studied population were 6, 42, 51 and 16. Co-infection was found in 153 men. Of those, 70 (19.7%) had a co-infection by 2 types, 37 (10.4%) by 3 types; 33 men (9.2%) by 4 types; 8 men (2.2%) by 5 types; 1 man (0.3%) by 6 types; 1 man (0.3%) by 7 types; 2 men (0.6%) by 8 types and 1 man (0.3%) by 9 types.

Conclusion: The most frequent HPV types were 6, 16, 42 and 51. Co-infection was found in 59% of our patients. This information is vital to drive future public health policies including massive public vaccination campaign.

Key words: DNA Probes, HPV; Infection; Men


Submitted for publication: June 25, 2013

Accepted after revision: September 17, 2013

INTRODUCTION

Infection by human papillomavirus (HPV) is the cause of several different diseases in men and women (1,2). Anogenital HPV related infection is the most prevalent common viral sexually transmitted infection worldwide (3). The World Health Organization (WHO) estimates that the prevalence of HPV infection is between nine and thirteen percent or about 630 million people (4). In the United States, CDC (Centers for Disease Control) estimates that approximately 26,000 new cancers attributable
to HPV occurs each year, including 18,000 among females and 8,000 among males (5). Genital warts are more frequently associated to HPV types 6 and 11 whereas HPV 16 and 18 are more commonly associated to cervical cancers.

HPV infection also prevails as the most common viral infection among the Brazilian population. Female HPV genotyping data shows prevalence rates of 57%, 23%, 5%, 4% and 3% for HPV genotypes 16, 18, 31, 33 and 56, respectively (6). A recent large epidemiological study demonstrated that among Brazilian men the prevalence of at least one type of HPV was 86.0%, while more than one HPV type, including high and low risk HPV, was identified in 39.5% of the samples (7). Nevertheless, data on Brazilian HPV infection and disease among males is scarce.

The aim of our study was to describe HPV genotypes prevalence data and to evaluate rates of co-infection with more than one HPV subtype in our male population.

**MATERIAL AND METHODS**

**Enrollment**

From March to October 2010, 366 men were referred to the Urological Division of Fleury Medicine and Health from private medical offices for evaluation of penile HPV related disease. Mean age was 35.6 ± 2.6 years (range 18-81 years). Patients were enrolled in a prospective manner and underwent genotyping, cytology and peniscopy. The study was approved by the Ethics Committee of Fleury Medicine and Health and informed consent was obtained from each patient.

**Inclusion criteria**

Males with age > 18 years old with active genital warts lesions; males with atypical penile lesions; males with a partner with a genital diagnosis of HPV and asymptomatic individuals willing to have a complete sexual transmitted diseases (STD) evaluation.

**Diagnostic Techniques**

After receiving proper information on the diagnostic methods, men were positioned in supine position. First, samples from the penile shaft, glans, balanopreputial sulcus and urethra were collected for cytology.

HPV genotyping materials were collected with a Digene® kit (Digene, USA). Samples were collected from the same sites as cytology examination. For cytology, specimens were preserved using the ThinPrep® (Hologic, USA) collection and preservation solution. HPV genotype micro-array detection was performed with Papillocheck® (Greiner Bio One, Germany). All men were tested for the following low-risk (LR) HPV types 6-11-40-42-43-44/55 as well as for the following high-risk (HR) HPV types 16-18-31-33-35-39-45-51-52-53-56-58-59-66-68-70-73-82.

Co-infection was defined as an infection with two or more HPV types.

All patients underwent peniscopy by a single physician. Acetic acid (5%) was spread in the genitalia to show small flat lesions. When indicated, biopsies were obtained using local anesthetics (infiltration of lidocaine 2%). Samples were examined by the Pathology Department.

**Statistical analysis**

All clinical data were collected and prospectively input in an Access® database (Microsoft, Redmond, Washington, USA). SPSS® (SPSS Inc., Chicago, Illinois, USA) were used for the statistical analysis.

**RESULTS**

From the cohort of men referred to our institution for HPV diagnostic evaluation, 256 men (72.1%) tested positive with genotype micro-array detection and 99 tested negative. Eleven inconclusive cases were excluded from analysis. So, our final sample for analysis was composed of 355 males at risk for HPV infection.

Overall HPV prevalence was 72.1%. The HPV prevalence distribution is shown on Table-1. Low risk HPV types represented 52.6% of our positive tests. Co-infection was found in 153 men, representing 59.7% of men who tested positive with an overall HPV co-infection prevalence of 43.1%. Of those, 70(19.7%) had co-infection by 2 types; 37 (10.4%) by 3 types; 33 men (9.2%) by 4
81.1% of the men tested positive. HPV infection was highly prevalent among middle-aged groups (50-59 years old), young adults (30-39 years) and among youth (18-29 years old), respectively 78.8%, 76.9% and 76.7%. HPV infection distribution shows that at least one HR-HPV type infection prevailed in most of men when divided by age (Figure-1). There was no correlation between high or low risk HPV infections and age. Also, we could not identify any preferential distribution of any HPV type and co-infection.

**Table 1 - HPV types prevalence.**

<table>
<thead>
<tr>
<th>HPV type</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>17.7</td>
</tr>
<tr>
<td>42</td>
<td>13.8</td>
</tr>
<tr>
<td>51</td>
<td>11.0</td>
</tr>
<tr>
<td>16</td>
<td>11.8</td>
</tr>
<tr>
<td>44-55</td>
<td>9.0</td>
</tr>
<tr>
<td>39</td>
<td>8.7</td>
</tr>
<tr>
<td>53</td>
<td>8.7</td>
</tr>
<tr>
<td>56</td>
<td>7.6</td>
</tr>
<tr>
<td>31</td>
<td>5.6</td>
</tr>
<tr>
<td>59</td>
<td>5.9</td>
</tr>
<tr>
<td>68</td>
<td>6.8</td>
</tr>
<tr>
<td>52</td>
<td>5.9</td>
</tr>
<tr>
<td>66</td>
<td>6.5</td>
</tr>
<tr>
<td>11</td>
<td>5.9</td>
</tr>
<tr>
<td>40</td>
<td>5.6</td>
</tr>
<tr>
<td>43</td>
<td>5.4</td>
</tr>
<tr>
<td>33</td>
<td>4.5</td>
</tr>
<tr>
<td>58</td>
<td>3.9</td>
</tr>
<tr>
<td>73</td>
<td>3.4</td>
</tr>
<tr>
<td>18</td>
<td>2.8</td>
</tr>
<tr>
<td>70</td>
<td>3.7</td>
</tr>
<tr>
<td>82</td>
<td>2.0</td>
</tr>
<tr>
<td>35</td>
<td>1.1</td>
</tr>
<tr>
<td>45</td>
<td>1.4</td>
</tr>
</tbody>
</table>

types; 8 men (2.2%) by 5 types; 1 man (0.3%) by 6 types; 1 man (0.3%) by 7 types; 2 men (0.6%) by 8 types and 1 man (0.3%) by 9 types.

Overall, at least one high-risk-HPV (HR-HPV) type was found in 58% of the men and in

**DISCUSSION**

Our study demonstrated some notable findings. At first, this is one of the largest studies on HPV’s infection prevalence and its genotype distribution among males.

In this study, HPV was highly prevalent, with 72.1% of men testing positive for the virus. These results are consonant with previous published data showing prevalence ranging from 1.3 to 72.9% (3,8-13). Our high number of infected men is probably due to selection, as our sample is
composed by men already referred for HPV testing with some degree of suspicious. This fact might also be the cause of our high number of at least one high-risk HPV type infection (58%) among our population. Regarding the observed high prevalence of high-risk HPV types among our studied population, it was also observed by others and may be consequence of the local restrict HPV vaccination policies (14).

In our study, the four more frequent observed HPV types were HPV 6, 42, 51 and 16, representing 54% of the total amount. This information is consistent with current published data where HPV types 6 and 16 are the most common types observed among men and women (6,7,15,16).

The genotyping description of the HPV infection distribution is an important diagnostic tool once men act as a reservoir for women’s infection. Therefore, HPV infection in men greatly affects disease risk in women and must be considered that, in fact, men is less frequently submitted to medical, in special, genital evaluation compared to women (17,18).

Furthermore, the knowledge of HPV prevalence, its subtype and age distribution might guide public health policies and prevention measures, including vaccination. In this regard, a quadrivalent HPV vaccine (HPV4) covering HPV types 6/11/16/18 is currently licensed for vaccination of 9-26 years old men.

Our findings should be interpreted in the context of the study design. Although our research scope was HPV prevalence, there are several limitations in this study. First, our cohort may not represent the entire population, as the studied patients already had a specific demand on HPV diagnosis prior to be referred to our laboratory. Therefore, a selection bias might be inferred since patients may represent a high risk population (e.g: previously treated for HPV, visible genital lesion or had a partner with diagnosed HPV). Moreover, our population was composed of a specific subset of the Brazilian population with full access to medical care. All patients were referred from private offices and had private medical insurance. Finally, in this study we could not study the epidemiology of the disease, including its transmission and potential influence of social and sexual habits on infection as well lack of follow-up data on each patient.

Future research should correlate these findings with women HPV prevalence. This correlation is of great importance considering the impact of the vaccination campaign as well as the transmission rate of the most prevalence HPV types found in our study.

CONCLUSIONS

This study demonstrates critical data on HPV prevalence and its subtype distribution among males with different age distribution. In our population, the most frequent HPV types were 6, 16, 42 and 51. Also, co-infection was found in almost 60% of our patients. In the future, this information should be useful to monitor the prevalence of vaccine-targeted HPV types after the introduction of vaccines.

CONFLICT OF INTEREST

None declared.

REFERENCES


Correspondence address:
Marcos Paulo Freire, MD
Rua Nova York 609 / 103B
São Paulo, Brazil, 04560-001
Telephone: + 55 11 7282-4508
E-mail: marcosfreire@grupofleury.com.br